Virginia is currently home to 1822 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home
NCT06639958
Recruiting
This clinical trial tests different programs to help patients with acute lymphoblastic leukemia (ALL) remember to take their medications during maintenance therapy at home. One problem with ALL maintenance treatment is remembering to take medicines at home like patients are supposed to. In maintenance, a medicine called 6-mercaptopurine or "6MP" is taken by mouth every day at home. In this study, 6MP prescriptions are filled into a special medication bottle called MEMS® which is fitted with a sp... Read More
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
02/11/2025
Locations: Inova Fairfax Hospital, Falls Church, Virginia
Conditions: Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
Register for Updates
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222
Recruiting
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Bon Secours St. Francis Medical Center, Midlothian, Virginia
Conditions: Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
Register for Updates
CCT-102 or Expectant Management in Delayed Pregnancy Loss
NCT06121063
Recruiting
A Phase 3, multi-center clinical trial of a CCT-102 regimen or expectant management to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss (DPL).
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
02/11/2025
Locations: Tidewater Clinical Research, Virginia Beach, Virginia
Conditions: Early Pregnancy Loss, Delayed Pregnancy Loss
Register for Updates
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430
Recruiting
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Solid Tumor, Adult, Refractory Cancer, Cutaneous Melanoma, Non-small Cell Lung Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, PMMR/MSS Adenocarcinoma of the Colon or Rectum
Register for Updates
RESPONDER-HF Trial
NCT05425459
Recruiting
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/11/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Heart Failure, Heart Failure, Diastolic
Register for Updates
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189
Recruiting
This First-in-human (FIH) trial for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with other therapies (cemiplimab, docetaxel, or a cytotoxic T-lymphocyte-associated protein 4 \[CTLA4\] antibody \[another investigational medicinal product\]) in patients with advanced or metastasized non-small cell lung cancer (NSCLC) and unresectable NSCLC after chemoradiotherapy (CRT). Furthermore, the trial aims to establish the safety a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Non-Small Cell Lung Cancer
Register for Updates
NP-G2-044 As Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies
NCT05023486
Recruiting
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Advanced or Metastatic Solid Tumor Malignancies
Register for Updates
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
NCT03901807
Recruiting
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Septic Shock, Endotoxemia
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005
Recruiting
This is a Phase 1a, first-in-human, open-label dose-escalation study to determine the RDR and/or MTD, and to assess the DLT of INV-9956. The safety, tolerability, PK/PD, and preliminary antitumor activity of INV-9956 will be assessed in adult patients with advanced mCRPC.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: NEXT Oncology, Fairfax, Virginia
Conditions: Advanced Metastatic Castration Resistant Prostate Cancer
Register for Updates
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients with Antibody-Mediated Rejection (AMR)
NCT06503731
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy of efgartigimod PH20 SC given by a prefilled syringe in participants with Antibody-Mediated Rejection (AMR) after kidney transplantation. After a screening period of up to 6 weeks, eligible participants will be randomized in a 1:1:1 ratio. The study drug will be administered subcutaneously while patients remain on their standard background immunosuppression therapy (tacrolimus, mycophenolate mofetil, steroids) during... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/10/2025
Locations: Virginia Commonwealth University (VCU) Medical Center Hume-Lee Transplant Center, Richmond, Virginia
Conditions: Antibody-mediated Rejection
Register for Updates
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants with Progressive Pulmonary Fibrosis
NCT06329401
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Inova Healthcare, Falls Church, Virginia
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
NCT06257355
Recruiting
This study will enroll subjects with recently formed corneal scars that resulted from a corneal insult presenting and diagnosed within the past approximately 30 days and not less than approximately 7 days. All subjects will be assigned to CSB-001 investigational treatment on Day 1. All subjects will dose with CSB-001 four times daily or three times daily starting on Day 1 and continue until Day 14. Subjects with a resolved scar at Day 7 will discontinue dosing and return to the clinic on Day 14.... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/10/2025
Locations: Virginia Eye Consultants, Norfolk, Virginia
Conditions: Corneal Scar
Register for Updates